Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 151 No. 5152 (2021)

HCV RNA quantification in capillary dried blood spots with the Xpert® HCV Viral Load test for diagnosing chronic HCV infection, monitoring treatment and detecting reinfection

  • Andrea Bregenzer
  • Cornelia Ottiger
  • Cornelia Krismer
  • Karin Sager
  • Christoph A. Fux
DOI
https://doi.org/10.4414/SMW.2021.w30089
Cite this as:
Swiss Med Wkly. 2021;151:w30089
Published
23.12.2021

Summary

BACKGROUND: For patients with difficult venous access after long-term intravenous drug use, rapid point-of-care hepatitis C virus (HCV) RNA quantification in capillary whole blood with the Xpert® HCV Viral Load Fingerstick (VL FS) test (60 minutes) is a convenient and reliable method for diagnosing chronic HCV infection, monitoring treatment and detecting reinfection. However, an expensive GeneXpert® system must be available on site. In decentralised settings with a low case-load, dried blood spot (DBS) testing might be an alternative.

METHODS: Between December 2019 and January 2021, patients with an indication for HCV RNA quantification and informed consent provided 100 µl capillary whole blood each for on-site Xpert® HCV VL FS testing (reference) and DBS testing in the laboratory. For the latter, 100 µl blood, collected with an EDTA Minivette®, were transferred to a Whatman® 903 filter card. After drying for at least 1 hour, the DBS sample was packed into a sealable plastic bag with desiccant and sent to the central laboratory of our hospital, where it was stored at –20°C. For HCV RNA extraction, the whole DBS was cut out with an 18-mm puncher and transferred into 1.3 ml guanidinium thiocyanate-containing buffer (provided by Cepheid®). After mixing and incubating at room temperature for 2–3 hours, 1 ml supernatant was analysed with the Xpert® HCV VL test (105 minutes) (filter paper absorbs 0.3 ml).

RESULTS: Of 109 paired samples from 67 patients, 38 (34.9%) were positive with the Xpert® HCV VL FS test. Sensitivity and specificity of DBS testing were 89.5% (34/38; 95% confidence interval [CI] 75.9–95.8%) and 97.2% (69/71; 95% CI 90.3–99.2%), respectively. The six (5.5%) discordant results (four false negative, two false positive) all were observed in samples with HCV RNA detectable below the limit of quantification after 2–8 weeks of pan-genotypic direct-acting antiviral treatment or 5 weeks after acute hepatitis C in a patient clearing HCV spontaneously. Quantifiable results (n = 30; 16 genotype 1, 7 genotype 3, 4 genotype 4, 1 genotype 1a and 3a, 2 unknown; HCV RNA range: 2.74–6.66 log IU/ml) correlated well (R2 = 0.981). On average, uncorrected DBS test results were 1.30 ± 0.14 log IU/ml lower than Xpert® HCV VL FS test results (~42 μl instead of the expected 1000 μl plasma used). Storage of DBS samples at room temperature for 7 days before freezing reduced HCV RNA by 0.29 ± 0.12 log IU/ml.

CONCLUSION: HCV RNA can reliably be quantified with the Xpert® HCV VL test in capillary dried blood spot samples. Thus, access to capillary HCV RNA quantification for diagnosing chronic HCV infection, monitoring treatment and detecting reinfection can be extended to decentralised settings with a low case load.

References

  1. WHO. 05/2016, Combating hepatitis B and C to reach elimination by 2030 - Advocacy brief; http://apps.who.int/iris/bitstream/10665/206453/1/WHO_HIV_2016.04_eng.pdf (Accessed: 2121 May 21)
  2. Chahine EB, Sucher AJ, Hemstreet BA. Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C. Ann Pharmacother. 2017 Jan;51(1):44–53. https://doi.org/10.1177/1060028016668897
  3. Puoti M, Foster GR, Wang S, Mutimer D, Gane E, Moreno C, et al. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: an integrated analysis of HCV genotype 1-6 patients without cirrhosis. J Hepatol. 2018 Aug;69(2):293–300. https://doi.org/10.1016/j.jhep.2018.03.007
  4. Brown RS Jr, Buti M, Rodrigues L, Chulanov V, Chuang WL, Aguilar H, et al. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial. J Hepatol. 2020 Mar;72(3):441–9. https://doi.org/10.1016/j.jhep.2019.10.020
  5. Aghemo A, Colombo M. Glecaprevir/Pibrentasvir: The Final Piece in the Hepatitis C Virus Treatment Puzzle? Gastroenterology. 2018 Mar;154(4):1195–6. https://doi.org/10.1053/j.gastro.2018.01.035
  6. Bundesamt für Gesundheit (BAG). BAG erweitert Vergütung von Medikamenten gegen Hepatitis C (27 Apr 17). Available from: https://www.bag.admin.ch/bag/de/home/das-bag/aktuell/medienmitteilungen.msg-id-66508.html
  7. Bundesamt für Gesundheit (BAG). Hepatitis C: Uneingeschränkte Vergütung der neuen Arzneimittel für alle Betroffenen (25 Sept 2017). Available from: https://www.bag.admin.ch/bag/de/home/das-bag/aktuell/medienmitteilungen.msg-id-68158.html
  8. Bregenzer A, Bruggmann P, Castro E, Moriggia A, Rothen M, Thurnheer MC, et al. Hepatitis C virus elimination in Swiss opioid agonist therapy programmes - the SAMMSU cohort. Swiss Med Wkly. 2021 Mar;151:w20460. https://doi.org/10.4414/smw.2021.20460
  9. Swiss Hepatitis Strategy 2014-2030 (January 2019, Version 4). Available from: https://www.hepatitis-schweiz.ch/download/2871/Process_Paper_14_02_2019.pdf (Accesssed: 22.02.21)
  10. Zahnd C, Brezzi M, Bertisch B, Giudici F, Keiser O. Analyse de Situation des Hépatites B et C en Suisse. Available from: https://www.bag.admin.ch/dam/bag/de/dokumente/mt/forschungsberichte/situationsanalyse-hepatitis-zusammenfassung.pdf.download.pdf/situationsanalyse-hepatitis-zusammenfassung-de.pdf (Accessed: 22.05.21)
  11. Schürch S, Fux CA, Dehler S, Conen A, Knuchel J, Friedl A, et al. Management of hepatitis C in opioid agonist therapy patients of the Swiss canton Aargau within and outside the cohort study. Swiss Med Wkly. 2020 Aug;150:w20317. https://doi.org/10.4414/smw.2020.20317
  12. Bregenzer A, Conen A, Knuchel J, Friedl A, Eigenmann F, Näf M, et al. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade. Swiss Med Wkly. 2017 Nov;147:w14544.
  13. Janjua NZ, Kuo M, Yu A, Alvarez M, Wong S, Cook D, et al. The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC). EBioMedicine. 2016 Oct;12:189–95. https://doi.org/10.1016/j.ebiom.2016.08.035
  14. Yehia BR, Schranz AJ, Umscheid CA, Lo Re V 3rd. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One. 2014 Jul;9(7):e101554. https://doi.org/10.1371/journal.pone.0101554
  15. Hajarizadeh B, Grebely J, McManus H, Estes C, Razavi H, Gray RT, et al. Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment. J Gastroenterol Hepatol. 2017 Jan;32(1):229–36. https://doi.org/10.1111/jgh.13453
  16. Hayes B, Briceno A, Asher A, Yu M, Evans JL, Hahn JA, et al. Preference, acceptability and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs. BMC Public Health. 2014 Jun;14(1):645. https://doi.org/10.1186/1471-2458-14-645
  17. McLeod A, Weir A, Aitken C, Gunson R, Templeton K, Molyneaux P, et al. Rise in testing and diagnosis associated with Scotland’s Action Plan on Hepatitis C and introduction of dried blood spot testing. J Epidemiol Community Health. 2014 Dec;68(12):1182–8. https://doi.org/10.1136/jech-2014-204451
  18. Tang W, Chen W, Amini A, Boeras D, Falconer J, Kelly H, et al. Diagnostic accuracy of tests to detect Hepatitis C antibody: a meta-analysis and review of the literature. BMC Infect Dis. 2017 Nov;17(S1 Suppl 1):695. https://doi.org/10.1186/s12879-017-2773-2
  19. Ivanova Reipold E, Easterbrook P, Trianni A, Panneer N, Krakower D, Ongarello S, et al. Optimising diagnosis of viraemic hepatitis C infection: the development of a target product profile. BMC Infect Dis. 2017 Nov;17(S1 Suppl 1):707. https://doi.org/10.1186/s12879-017-2770-5
  20. Lamoury FM, Bajis S, Hajarizadeh B, Marshall AD, Martinello M, Ivanova E, et al.; LiveRLife Study Group. Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay. J Infect Dis. 2018 May;217(12):1889–96. https://doi.org/10.1093/infdis/jiy114
  21. Bregenzer A, Warmann N, Ottiger C, Fux CA. Rapid point-of-care HCV RNA quantification in capillary whole blood for diagnosing chronic HCV infection, monitoring treatment and detecting reinfection. Swiss Med Wkly. 2019 Oct;149:w20137. https://doi.org/10.4414/smw.2019.20137
  22. Greenman J, Roberts T, Cohn J, Messac L. Dried blood spot in the genotyping, quantification and storage of HCV RNA: a systematic literature review. J Viral Hepat. 2015 Apr;22(4):353–61. https://doi.org/10.1111/jvh.12345
  23. Lange B, Roberts T, Cohn J, Greenman J, Camp J, Ishizaki A, et al. Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples - a systematic review and meta-analysis. BMC Infect Dis. 2017 Nov;17(S1 Suppl 1):693. https://doi.org/10.1186/s12879-017-2776-z
  24. Bennett S, Gunson RN, McAllister GE, Hutchinson SJ, Goldberg DJ, Cameron SO, et al. Detection of hepatitis C virus RNA in dried blood spots. J Clin Virol. 2012 Jun;54(2):106–9. https://doi.org/10.1016/j.jcv.2012.02.004
  25. McHugh MP, Wu AH, Chevaliez S, Pawlotsky JM, Hallin M, Templeton KE. Multicenter Evaluation of the Cepheid Xpert Hepatitis C Virus Viral Load Assay. J Clin Microbiol. 2017 May;55(5):1550–6. https://doi.org/10.1128/JCM.02460-16
  26. Gupta E, Agarwala P, Kumar G, Maiwall R, Sarin SK. Point -of -care testing (POCT) in molecular diagnostics: performance evaluation of GeneXpert HCV RNA test in diagnosing and monitoring of HCV infection. J Clin Virol. 2017 Mar;88:46–51. https://doi.org/10.1016/j.jcv.2017.01.006
  27. Cepheid®, Home → Tests → Virology → Xpert HCV Viral Load, https://www.cepheid.com/en/tests/Virology/Xpert-HCV-Viral-Load (Accessed: 2021 May 22)
  28. Wlassow M, Poiteau L, Roudot-Thoraval F, Rosa I, Soulier A, Hézode C, et al. The new Xpert HCV viral load real-time PCR assay accurately quantifies hepatitis C virus RNA in serum and whole-blood specimens. J Clin Virol. 2019 Aug;117:80–4. https://doi.org/10.1016/j.jcv.2019.06.007
  29. Santos C, Reis A, Dos Santos CV, Damas C, Silva MH, Viana MV, et al. The use of real-time PCR to detect hepatitis C virus RNA in dried blood spots from Brazilian patients infected chronically. J Virol Methods. 2012 Jan;179(1):17–20. https://doi.org/10.1016/j.jviromet.2011.06.012
  30. Stapleton JT, Klinzman D, Schmidt WN, Pfaller MA, Wu P, LaBrecque DR, et al. Prospective comparison of whole-blood- and plasma-based hepatitis C virus RNA detection systems: improved detection using whole blood as the source of viral RNA. J Clin Microbiol. 1999 Mar;37(3):484–9. https://doi.org/10.1128/JCM.37.3.484-489.1999
  31. Tuaillon E, Mondain AM, Meroueh F, Ottomani L, Picot MC, Nagot N, et al. Dried blood spot for hepatitis C virus serology and molecular testing. Hepatology. 2010 Mar;51(3):752–8.
  32. Soulier A, Poiteau L, Rosa I, Hézode C, Roudot-Thoraval F, Pawlotsky JM, et al. Dried Blood Spots: A Tool to Ensure Broad Access to Hepatitis C Screening, Diagnosis, and Treatment Monitoring. J Infect Dis. 2016 Apr;213(7):1087–95. https://doi.org/10.1093/infdis/jiv423
  33. van Deursen P, Oosterlaken T, Andre P, Verhoeven A, Bertens L, Trabaud MA, et al. Measuring human immunodeficiency virus type 1 RNA loads in dried blood spot specimens using NucliSENS EasyQ HIV-1 v2.0. J Clin Virol. 2010 Feb;47(2):120–5. https://doi.org/10.1016/j.jcv.2009.11.021
  34. Abe K, Konomi N. Hepatitis C virus RNA in dried serum spotted onto filter paper is stable at room temperature. J Clin Microbiol. 1998 Oct;36(10):3070–2. https://doi.org/10.1128/JCM.36.10.3070-3072.1998
  35. Catlett B, Carrera A, Starr M, Applegate TL, Lowe P, Grebely J, et al. Performance evaluation of the Hologic Aptima HCV Quant Dx assay for detection of HCV RNA from dried blood spots. J Clin Virol. 2019 Mar;112:40–4. https://doi.org/10.1016/j.jcv.2019.01.010
  36. Solmone M, Girardi E, Costa F, Pucillo L, Ippolito G, Capobianchi MR. Simple and reliable method for detection and genotyping of hepatitis C virus RNA in dried blood spots stored at room temperature. J Clin Microbiol. 2002 Sep;40(9):3512–4. https://doi.org/10.1128/JCM.40.9.3512-3514.2002
  37. Moradpour D, Fehr J, Semela D, Rauch A, Müllhaupt B. Treatment of Chronic Hepatitis C – January 2021 Update Expert Opinion SASL, SSG and SSI. Available from: https://www.sginf.ch/files/sasl-ssg-ssi_eos_hepc_jan2021_1.pdf (Accessed: 2021 May 20)
  38. European Association for the Study of the Liver Recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73:1170–218. https://doi.org/10.1016/j.jhep.2020.08.018
  39. Ghany MG, Morgan TR. AASLD-ISDA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71:686–721. https://doi.org/10.1002/hep.31060
  40. Hajarizadeh B, Grady B, Page K, Kim AY, McGovern BH, Cox AL, et al.; InC3 Study Group. Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study. PLoS One. 2015 Apr;10(4):e0122232. https://doi.org/10.1371/journal.pone.0122232
  41. Bertisch B, Brezzi M, Negro F, Müllhaupt B, Ottiger C, Künzler-Heule P, et al.; Swiss Hepatitis C Cohort Study. Very Low Hepatitis C Viral Loads in Treatment-naive Persons: Do They Compromise Hepatitis C Virus Antigen Testing? Clin Infect Dis. 2020 Feb;70(4):653–9.
  42. WHO guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017
  43. Offizielle Website der nationalen Substitutionsstatistik, 2016-2021. Available from: https://www.substitution.ch/de/jahrliche_statistik.html&year=2020&canton=ag (Accessed: 2021 May 20)
  44. Buchanan R, Cooper K, Grellier L, Khakoo SI, Parkes J. The testing of people with any risk factor for hepatitis C in community pharmacies is cost-effective. J Viral Hepat. 2020 Jan;27(1):36–44. https://doi.org/10.1111/jvh.13207
  45. Buchanan R, Hassan-Hicks P, Noble K, Grellier L, Parkes J, Khakoo SI. Integrating community pharmacy testing for hepatitis C with specialist care. Clin Pharm. 2016;8(8):243–7.
  46. Kugelmas M, Pedicone LD, Lio I, Simon S, Pietrandoni G, Hepatitis C. Hepatitis C Point-of-Care Screening in Retail Pharmacies in the United States. Gastroenterol Hepatol (N Y). 2017 Feb;13(2):98–104.
  47. Radley A, Tait J, Dillon JF. DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy. Int J Drug Policy. 2017 Sep;47:126–36. https://doi.org/10.1016/j.drugpo.2017.05.042
  48. Radley A, de Bruin M, Inglis SK, Donnan PT, Hapca A, Barclay ST, et al. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial. Lancet Gastroenterol Hepatol. 2020 Sep;5(9):809–18. https://doi.org/10.1016/S2468-1253(20)30120-5
  49. Wade AJ. Can community pharmacists treat hepatitis C virus? Lancet Gastroenterol Hepatol. 2020 Sep;5(9):790–1. https://doi.org/10.1016/S2468-1253(20)30184-9
  50. Bajis S, Applegate TL, Grebely J, Matthews GV, Dore GJ. Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic. J Infect Dis. 2020 Nov;222 Suppl 9:S758–72. https://doi.org/10.1093/infdis/jiaa366
  51. Bundesamt für Gesundheit BAG. (03/2019) Hepatitis C bei Drogenkonsumierenden: Richtlinien mit settingspezifischen Factsheets. Available from: https://www.bag.admin.ch/dam/bag/de/dokumente/mt/infektionskrankheiten/hepatitis-c/richtlinien-hepatitis-c-drogen.pdf.download.pdf/richtlinien-hepatitis-c-drogen-de.pdf (Accessed: 2021 May 20)
  52. Smookler D, Vanderhoff A, Biondi MJ, Valencia J, Ryan P, Karkada J, Hong R, Sattar I, Mandel E, Gjevori M, Casey J, Fletcher D, Shah H, Hansen BE, Capraru C, Janssen HLA, Lazarus JV, Feld JJ. Reducing Read Time of Point-of-Care Test Does Not Affect Detection of Hepatitis C Virus and Reduces Need for Reflex RNA. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31068-5. doi: https://doi.org/10.1016/j.cgh.2020.07.058. Epub ahead of print. PMID: 32763480.
  53. Pallarés C, Carvalho-Gomes Â, Hontangas V, Conde I, Di Maira T, Aguilera V, et al. Performance of the OraQuick Hepatitis C virus antibody test in oral fluid and fingerstick blood before and after treatment-induced viral clearance. J Clin Virol. 2018 May;102:77–83. https://doi.org/10.1016/j.jcv.2018.02.016
  54. Khuroo MS, Khuroo NS, Khuroo MS. Diagnostic accuracy of point-of-care tests for hepatitis C virus infection: a systematic review and meta-analysis. PLoS One. 2015 Mar;10(3):e0121450. https://doi.org/10.1371/journal.pone.0121450
  55. Chevaliez S, Poiteau L, Rosa I, Soulier A, Roudot-Thoraval F, Laperche S, et al. Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care. Clin Microbiol Infect. 2016 May;22(5):459.e1–6. https://doi.org/10.1016/j.cmi.2016.01.009
  56. Lee SR, Kardos KW, Schiff E, Berne CA, Mounzer K, Banks AT, et al. Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. J Virol Methods. 2011 Mar;172(1-2):27–31. https://doi.org/10.1016/j.jviromet.2010.12.009
  57. The Kirby Institute. Monitoring hepatitis C treatment uptake in Australia (Issue 10). The Kirby Institute, UNSW Sydney, NSW, Australia, June 2019 (available online at: https://kirby.unsw.edu.au/report/monitoring-hepatitis-c-treatment-uptake-australia-issue-10-june-2019). For more information, contact Dr Behzad Hajari (bhajarizadeh@kirby.unsw.edu.au) or Professor Greg Dore (gdore@kirby.unsw.edu.au).
  58. Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, et al. Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs. Clin Infect Dis. 2020 Apr;70(9):1900–6. https://doi.org/10.1093/cid/ciz546
  59. Palmer AY, Wade AJ, Draper B, Howell J, Doyle JS, Petrie D, et al. A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment. Int J Drug Policy. 2020 Feb;76:102633. https://doi.org/10.1016/j.drugpo.2019.102633
  60. Loustaud-Ratti V, Debette-Gratien M, Carrier P. European Association for the Study of the Liver and French hepatitis C recent guidelines: the paradigm shift. World J Hepatol. 2018 Oct;10(10):639–44. https://doi.org/10.4254/wjh.v10.i10.639
  61. Ryan P, Valencia J, Cuevas G, Troya J, Ramon C, Rodríguez A, et al. HCV screening based on dried blood samples and linkage to care in people who use drugs: A prospective study. Int J Drug Policy. 2021 Jun;92:103134. https://doi.org/10.1016/j.drugpo.2021.103134
  62. WHO Prequalification of In Vitro Diagnostics. Public Report (June/2016, version 2.0), Product: Xpert® HIV-1 Qual Assay, WHO reference number: PQDx 0259-070-00, (available online at: https://www.who.int/diagnostics_laboratory/evaluations/pq-list/hiv-vrl/160613PQPublicReport_0259-0700-00_XpertQualHIV_v2.pdf)